Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.

Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR Jr, Thal L, Aisen PS; Alzheimer's Disease Cooperative Study Group.

Arch Gen Psychiatry. 2011 Aug;68(8):853-61. doi: 10.1001/archgenpsychiatry.2011.72.

PMID:
21810649
2.

Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.

Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L; Alzheimer's Disease Cooperative Study; Valproate Nursing Home Study Group.

Am J Geriatr Psychiatry. 2005 Nov;13(11):942-9.

PMID:
16286437
3.

Valproate preparations for agitation in dementia.

Lonergan E, Luxenberg J.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD003945. doi: 10.1002/14651858.CD003945.pub3. Review.

PMID:
19588348
4.

Valproic acid for agitation in dementia.

Lonergan ET, Cameron M, Luxenberg J.

Cochrane Database Syst Rev. 2004;(2):CD003945. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD003945.

PMID:
15106227
6.
7.

A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.

Herrmann N, Lanctôt KL, Rothenburg LS, Eryavec G.

Dement Geriatr Cogn Disord. 2007;23(2):116-9. Epub 2006 Dec 4.

PMID:
17148938
8.

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group.

JAMA. 2014 Feb 19;311(7):682-91. doi: 10.1001/jama.2014.93.

9.

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS.

JAMA. 2010 Nov 3;304(17):1903-11. doi: 10.1001/jama.2010.1510.

10.

Relapse risk after discontinuation of risperidone in Alzheimer's disease.

Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B.

N Engl J Med. 2012 Oct 18;367(16):1497-507. doi: 10.1056/NEJMoa1114058. Erratum in: N Engl J Med. 2012 Dec 20;367(25):2458.

11.

Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.

Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, Forbes A.

Am J Geriatr Psychiatry. 2007 Nov;15(11):918-31.

PMID:
17974864
12.

A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.

Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K.

Int J Geriatr Psychiatry. 2011 Sep;26(9):937-43. doi: 10.1002/gps.2630. Epub 2010 Dec 28.

13.

Valproate therapy for agitation in dementia: open-label extension of a double-blind trial.

Porsteinsson AP, Tariot PN, Jakimovich LJ, Kowalski N, Holt C, Erb R, Cox C.

Am J Geriatr Psychiatry. 2003 Jul-Aug;11(4):434-40.

PMID:
12837672
14.

Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.

Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, De La Gandara JE, Agronin M, Davis CS, Nguyen U, Shin P, Tariot PN, Siffert J.

JAMA. 2015 Sep 22-29;314(12):1242-54. doi: 10.1001/jama.2015.10214.

15.

Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis.

Gobbi G, Gaudreau PO, Leblanc N.

J Clin Psychopharmacol. 2006 Oct;26(5):467-73.

PMID:
16974186
16.

Chronic divalproex sodium use and brain atrophy in Alzheimer disease.

Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, Jack CR Jr, Weiner MW, Thomas RG, Schneider LS, Tariot PN; Alzheimer's Disease Cooperative Study.

Neurology. 2011 Sep 27;77(13):1263-71. doi: 10.1212/WNL.0b013e318230a16c. Epub 2011 Sep 14.

17.

Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.

Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S.

Adv Drug Deliv Rev. 2002 Dec 7;54(12):1567-77. Review.

PMID:
12453674
18.

Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease.

Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST.

Arch Neurol. 1999 Oct;56(10):1266-72.

PMID:
10520944
19.

A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F.

J Clin Psychiatry. 2003 Feb;64(2):134-43.

PMID:
12633121
20.

Supplemental Content

Support Center